Genentech Has Mixed Results In Cancer Fight
Genentech and Biogen Idec announced that their drug Rituxan was able to slow the progression of lymphocytic leukemia in a late-stage trial that treated patients who had relapses after traditional chemotherapy. The success should help make up for the sting Monday of dissapointing results from tests of a lung cancer treatment
This entry was posted on Thursday, October 9th, 2008 at 12:51 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.